Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced new preclinical data demonstrating the potential of INTASYL self-delivering siRNA targeting Cbl-b to improve natural killer (NK) cell activity for adoptive cell therapy, presenting at the 10th Immunotherapy of Cancer Conference in Germany. The data shows the potential for a more effective cell therapy for hematological malignancies.
01/31/2024 - 08:00 AM
--New preclinical data to be presented at Immunotherapy Conference in Germany
MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that new preclinical data demonstrating the potential of INTASYL self-delivering siRNA targeting Cbl-b improves natural killer (NK) cell activity for adoptive cell therapy and may result in a more effective cell therapy for hematological malignancies will be presented at the 10th Immunotherapy of Cancer Conference (ITOC10), which will be held in Munich, Germany from March 21-23, 2024.
Presentation Details are as follows:
Title: Enhancing NK cell cytotoxicity against tumor cells with a novel self-delivering RNAi compound targeting Cbl-b Poster Number: P01.03 Topic: 01.Emerging concepts / New Agents Presenting Author: Melissa Maxwell Date and Time: 18:00 hrs Thursday, March 21, 2024 18:00-19:00 hrs Friday, March 22, 2024 Location: Ludwig Maximilian University Campus Großhadern, Lecture Room 3, Marchioninistrasse 15 81377 Munich, Germany
The poster presentation will be accessible in person and will also be available on March 21st , on Phio’s website.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.www.phiopharma.com .
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Examples of forward-looking statements include statements regarding the potential of an INTASYL compound targeting Cbl-b to demonstrate improved NK cell activity and to result in a more effective therapy for hematological malignancies. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact: ir@phiopharma.com
PR Contact adams@bridgeviewmedia.com
The ticker symbol for Phio Pharmaceuticals Corp. is PHIO.
The new preclinical data demonstrates the potential of INTASYL self-delivering siRNA targeting Cbl-b to improve natural killer (NK) cell activity for adoptive cell therapy, potentially resulting in a more effective cell therapy for hematological malignancies.
The 10th Immunotherapy of Cancer Conference will be held in Munich, Germany.
The poster presentation will be accessible in person on March 21st and will also be available on Phio’s website.
The presenting author of the poster presentation is Melissa Maxwell.
